RGEN analyst estimates
Repligen (RGEN) analyst ratings, the average price target and its range, and every firm's latest call.
RGEN analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 28, 2026 | RBC Capital | Repligen price target raised to $200 from $185 at RBC Capital | $200.00 |
| Oct 19, 2026 | Canaccord Genuity | Repligen price target raised to $180 from $145 at Canaccord | $180.00 |
| Oct 7, 2026 | Barclays | Repligen price target raised to $225 from $175 at Barclays | $225.00 |
| Sep 9, 2026 | UBS | Repligen assumed with a Buy at UBS | $225.00 |
| Jul 6, 2026 | Evercore ISI | Repligen price target raised to $160 from $150 at Evercore ISI | $160.00 |
| May 14, 2026 | RBC Capital | Repligen resumed with an Outperform at RBC Capital | $160.00 |
| May 5, 2026 | Jefferies | Repligen price target lowered to $142 from $152 at Jefferies | $142.00 |
| Apr 20, 2026 | Canaccord Genuity | Repligen price target lowered to $145 from $165 at Canaccord | $145.00 |
| Apr 17, 2026 | Redburn Partners | Repligen initiated with a Buy at Rothschild & Co Redburn | $160.00 |
| Apr 14, 2026 | Barclays | Repligen price target lowered to $145 from $175 at Barclays | $145.00 |
| Jan 16, 2026 | UBS | Repligen price target raised to $200 from $190 at UBS | $200.00 |
| Dec 15, 2025 | Barclays | Repligen price target raised to $200 from $175 at Barclays | $200.00 |
| Dec 15, 2025 | Wells Fargo | Repligen price target raised to $190 from $175 at Wells Fargo | $190.00 |
| Oct 29, 2025 | Barclays | Repligen price target raised to $175 from $160 at Barclays | $175.00 |
| Oct 29, 2025 | Canaccord Genuity | Repligen price target raised to $165 from $150 at Canaccord | $165.00 |
- 11 firms rate RGEN: 10 buy, 1 hold, 0 sell.
- The average price target is $188.67 from 6 analysts, from $142.00 to $225.00.
Updated 2026-11-02 23:58 UTC